🏭 The investment will create more than 500 jobs and strengthen France’s ability to produce essential medicines.
💉 The investment includes a new facility in Vitry-sur-Seine to double monoclonal antibody production capacity.
🧪 Sanofi will also invest in new capacity for biologics formulation and packaging in Le Trait.
💰 In Lyon Gerland, Sanofi will invest €10 million ($10.9 million) to locate the production of TZield in France.
💊 This investment is part of Sanofi’s commitment to keeping production of medicines and vaccines in France.
Introduction:
Sanofi, a pharmaceutical company, has announced an investment of over €1 billion ($1.1 billion) to create new bioproduction capacity at its sites in France. This investment aims to strengthen France’s ability to produce essential medicines and create more than 500 jobs. It is part of Sanofi’s commitment to keep production of medicines and vaccines in France, totaling more than €3.5 billion ($3.8 billion) since the COVID-19 pandemic.
- Sanofi plans to invest €1 billion to build a new facility in Vitry-sur-Seine, which will double the site’s monoclonal antibody production capacity. This facility will produce biologics for chronic obstructive pulmonary disorder (COPD), asthma, multiple sclerosis, and type 1 diabetes.
- The company will invest €100 million in the Le Trait site in Normandy to develop new capacity for biologics formulation, filling, device assembly, and packaging. This investment will support the launch of future biologics and vaccines, as well as the growth of Dupixent, an inflammatory disease drug.
- In Lyon Gerland, Sanofi is investing €10 million to locate the production of TZield®, a biologic for type 1 diabetes, in France. This investment aims to bring the manufacturing of TZield® within Europe.
- Sanofi carries out more than 60 percent of its global production in the European Union and sources only five percent of its active ingredients in Asia, compared to the industry average of 80 percent. This investment further reinforces Sanofi’s commitment to local production.
Conclusion:
Sanofi’s investment of over €1 billion in new bioproduction capacity in France demonstrates its commitment to local production and strengthens France’s ability to produce essential medicines. This investment will create jobs and support the growth of biologics and vaccines. Sanofi’s focus on local production and reducing reliance on external suppliers aligns with its goal of meeting public health challenges and ensuring the availability of critical medicines.
